IGFBP2

Across TCGA pan-cancer cohorts, IGFBP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGFBP2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IGFBP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IGFBP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where IGFBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.903	0.620	.001	22	view →
CCRCC	OS	Quartile	III,IV	0.471	0.777	.022	14	view →
LUAD	DFS	Median	All	0.485	0.735	.015	10	view →
GBM	OS	Median	All	0.269	0.501	.008	8	view →
LSCC	DFS	Quartile	III,IV	1.000	0.388	.014	8	view →
PDAC	OS	Tertile	All	0.907	0.805	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IGFBP2–HNSC (DFS)

Open the HNSC breakdown →